| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.41 | 3e-14 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.4 | 8e-10 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.28 | 1e-08 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.3 | 1e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-07 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.29 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.31 | 1e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 3e-06 |